Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Regulation topic
No spam. Unsubscribe anytime.
Committee holds H 864 on kratom to March 25 after divided testimony
Summary
Lawmakers heard emotional testimony on H 864 debating a ban versus regulation of kratom; supporters cited overdose harms and presence in detention facilities, while industry and retailers urged regulation and age/labeling limits. The committee voted 11–5 to hold the bill to March 25, 2026.
Supporters of H 864 told the House Health & Welfare Committee that kratom and its derivatives have harmed families and that easy access should be curtailed. Multiple witnesses, including members of law enforcement associations and people who identified themselves as family members of those lost to the substance, urged stronger restrictions or a ban to protect youth and populations in detention settings.
Opponents—representatives of retailers, the American Kratom Association and individual sellers—urged regulation instead of prohibition, recommending age limits and labeling requirements to preserve consumer choice and access for pain relief. The record notes industry witnesses argued the U.S. Food and Drug Administration’s primary concern is with 7‑OH synthetic kratom derivatives rather than whole‑leaf products.
Committee members offered competing views on public safety and regulatory consistency. In closing remarks Rep. Pohanka and Rep. Bingham summarized supporters’ concerns, noting the Drug Enforcement Administration ‘‘has identified [kratom] as a drug of concern’’ and that "this legislation provides a pause for study and public protection." The minutes also report the committee was told there have been 83 overdose deaths in Idaho since 2021 that included natural‑leaf kratom.
On motions, Rep. Egbert first moved to send H 864 to the floor with no recommendation; Rep. Beiswenger then moved to lay the bill on the table and Rep. Rubel offered an amended substitute to hold H 864 to a time certain of March 25, 2026. The roll‑call on the amended substitute carried 11 AYE and 5 NAY (AYE: Vander Woude, Healey, Redman, Burgoyne, Cayler, Fuhriman, Leavitt, Thompson, Stone, Tanner(13), Rubel; NAY: Erickson, Wheeler, Beiswenger, McCann, Egbert), so the bill was held to March 25.
The committee did not adopt specific statutory language at this hearing and directed no additional committee votes beyond placing H 864 on the March 25 time certain. Next steps: H 864 will be returned to committee or taken up at the March 25 session per the committee’s hold.
